Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria

Abstract

Benefits of omalizumab treatment were evident early (before week 4) in some patients and persisted to week 24. Use of 300 mg of omalizumab demonstrated best results in controlling CIU/CSU symptoms.